Uber bets on affordability with shared fixed-route rides, expanded passes
The ride-sharing app has been looking to invest in more affordable transport and delivery offerings to widen its user base and combat slowing revenue growth in an uncertain economic environment.
Uber's new "Route Share" ride option will cost half as much as the company's UberX ride-hail service, by providing pickups every 20 minutes along busy commute corridors.
Initially available in cities such as New York, San Francisco and Chicago, Route Share will operate during weekday rush hours and Uber is considering partnering with employers to integrate pre-tax commuter benefits.
The company is also expanding ride passes that help users lock-in lower fares and keep costs predictable.
These ride passes will be available in major U.S. cities such as Chicago, Dallas, and San Francisco, and will be expanded to teen accounts later this year.
Uber unveiled Price Lock Pass for $2.99 in February and it was initially available in a few U.S. markets. The feature will now be available across several cities in the United States and expand throughout the country and Brazil this year, the company said.
The company had announced a partnership with Volkswagen (VOWG.DE), opens new tab to deploy a fleet of thousands of the German automaker's fully electric ID. Buzz AD vehicles as robotaxis next year. The vehicles will also be used for shared self-driving taxi rides.
Uber is also scaling its tie-up with Waymo in Austin, aiming to increase the number of robotaxis to hundreds of vehicles in the coming months.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
9 minutes ago
- Reuters
Indexes slip as investors consider tariff impact
NEW YORK, Aug 5 (Reuters) - U.S. stocks were down slightly on Tuesday as investors weighed the impact of tariffs, with U.S. President Donald Trump saying the U.S. could impose a "small tariff" on pharmaceutical imports before increasing the rate subsequently. Investors digested comments from several companies on tariffs. Shares of KFC parent Yum Brands (YUM.N), opens new tab were down 4.8% after the company missed estimates for the second quarter, as steep trade duties restricted consumer spending. Caterpillar (CAT.N), opens new tab warned of an up to $1.5 billion hit in 2025, but its shares were up 0.2%. Trump also signaled an announcement on tariffs on semiconductors and chips in the "next week or so." The S&P 500 technology (.SPLRCT), opens new tab index was down 0.3% and the Philadelphia Semiconductor Index (.SOX), opens new tab was down 0.6%. "Today's market action reflects investors that are merely in pause mode," said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis, Minnesota. While the backdrop for equities remains constructive for the year, "clearly near-term there are some headwinds," he said, including elevated valuations given recent record highs in the S&P 500. "The impact of tariffs remains a work in progress," he noted. Earlier in the day, data showed ISM's nonmanufacturing purchasing managers index (PMI) slipped to 50.1 last month from 50.8 in June, as little changes in orders and weaker hiring, alongside rising input costs. The Dow Jones Industrial Average (.DJI), opens new tab fell 54.49 points, or 0.12%, to 44,120.40, the S&P 500 (.SPX), opens new tab lost 24.25 points, or 0.38%, to 6,305.69 and the Nasdaq Composite (.IXIC), opens new tab lost 106.49 points, or 0.51%, to 20,947.19. Shares of Marriott International (MAR.O), opens new tab were down 0.2% after it cut its annual forecast on slowing travel demand. Stocks sold off on Friday after a disappointing July jobs data and sharp downward revisions to prior months, but indexes bounced back on Monday. Advancing issues outnumbered decliners by a 1.12-to-1 ratio on the NYSE. There were 141 new highs and 59 new lows on the NYSE. On the Nasdaq, 1,989 stocks rose and 2,476 fell as declining issues outnumbered advancers by a 1.24-to-1 ratio.
Reuters
9 minutes ago
- Reuters
Wall Street indexes fall, oil drops for fourth straight session
NEW YORK/LONDON, Aug 5 (Reuters) - Wall Street stock indexes fell on Tuesday, under pressure from weaker than expected U.S. economic data, as equities in Europe and Asia notched gains. U.S. services sector activity unexpectedly flatlined in July with little change in orders and a further weakening in employment even as input costs climbed by the most in nearly three years, highlighting the uncertainty over the impact of Trump's tariff policy on businesses. U.S. Treasury yields regained ground, shaking off pressure from the disappointing data. The Dow Jones Industrial Average (.DJI), opens new tab fell 67.10 points, or 0.15%, to 44,106.54, the S&P 500 (.SPX), opens new tab fell 23.05 points, or 0.36%, to 6,306.89 and the Nasdaq Composite (.IXIC), opens new tab fell 89.87 points, or 0.43%, to 20,963.72. The U.S. dollar steadied as investors raised bets the Federal Reserve would act to prop up the world's largest economy. Gold prices turned higher, and oil retreated on rising OPEC+ supply and worries of weaker global demand. On Monday, U.S. shares had rallied on generally positive earnings reports and increasing bets for a September rate cut from the Fed after disappointing jobs data last week. The pan-European STOXX 600 (.STOXX), opens new tab index edged up 0.15%, Most regional bourses also traded higher, echoing the strength across Asia markets, where MSCI's broadest index of Asia-Pacific shares outside Japan (.MIAPJ0000PUS), opens new tab closed up 0.77%. European earnings season was in full swing, with Diageo (DGE.L), opens new tab jumping 4.9% after forecasting flat 2026 sales despite U.S. tariffs. "The removal of the uncertainty is one factor that is helping European markets, even if the tariff rate is probably a bit higher than what market participants or European politicians would have expected or hoped to see," said Amelie Derambure, senior multi-asset portfolio manager at Amundi. "The question is whether bad news is bad news (economy slowing down) or it's good news (Fed moving towards rate cuts). Our view is that it depends on how bad is the data and what's priced in," Jefferies strategist Mohit Kumar said. "A modest weakening of the economy would be good news as it should be more easing from the Fed. However, a sustained and sharp rise in unemployment rates would be a negative as it would raise concerns over growth and earnings," he said. The dollar index , which measures the greenback against a basket of currencies including the yen and the euro, rose 0.14% to 98.76, with the euro up 0.03% at $1.1574. Odds for a September rate cut now stand at about 94%, according to CME Fedwatch, from a 63% chance seen on July 28. Market participants see at least two quarter-point cuts by the end of this year. The yield on 2-year notes rose 3.9 basis points to 3.72%, from 3.681% late on Monday. News that Trump could fill a governorship position at the Fed early added to worries about politicization of interest rate policy. Trump again threatened to raise tariffs on goods from India from the 25% level announced last month due to its Russian oil purchases, while New Delhi called his attack "unjustified" and vowed to protect its economic interests. "Whether the threat of secondary sanctions on India's financing of Russia is the core goal remains to be seen," strategists at ING said. "Or indeed, this move may be increased U.S. leverage on India to open up its domestic economy to agricultural imports or commitments to buy U.S. energy instead." Oil prices dropped for a fourth day, with concern mounting about economic growth and the potential for oversupply. Brent crude futures were down 1.48% at $67.74 per barrel and U.S. crude retreated 1.55% to $65.26. The second-quarter U.S. earnings season is winding down, but investors are still awaiting results this week from companies including Walt Disney (DIS.N), opens new tab and Caterpillar (CAT.N), opens new tab. Data on Tuesday showed business activity in the euro zone grew at a slightly faster pace in July than in June, but remained sluggish. A separate UK survey showed British businesses recorded their largest drop in new orders in almost three years in July and cutting staff by the most in six months. Data from Asia's two biggest economies showed resilience in their service sectors. In Japan, the S&P Global final services purchasing managers' index (PMI) to 53.6 in July from 51.7 in June for the strongest expansion since February. China's services activity last month at its fastest pace in more than a year. Spot gold prices rose 0.22% to $3,380.10 an ounce.
Reuters
9 minutes ago
- Reuters
Novo Nordisk expands lawsuits against weight-loss drug compounders
Aug 5 (Reuters) - Danish drugmaker Novo Nordisk ( opens new tab said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. The new lawsuits target pharmacies and telehealth companies producing compounded versions of semaglutide "under the fake guise of personalization", Novo said, without naming the companies. Shares of major telehealth firm Hims & Hers (HIMS.N), opens new tab extended losses to fall nearly 13% in afternoon trade. It had earlier reported weaker-than-expected quarterly revenue. A Reuters search of legal filings found some cases filed by Novo in California dated Aug. 4 but none regarding San Francisco-based Hims. Hims was not immediately available for comment. Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. These companies were briefly allowed to produce hundreds of thousands of compounded doses of Novo's obesity and diabetes drugs when the Food and Drug Administration said they were in short supply. When the agency later banned the sale of these copies, Hims and Hers shifted to creating versions of semaglutide in personalized doses not accessible through the branded manufacturers. Novo's lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded "semaglutide" under the guise of personalized medicine. In reality, these are knockoffs that have not been approved as safe and effective and are often made with illicit foreign active pharmaceutical ingredients (API), Novo said. It did not immediately respond to a Reuters query on which companies were being named in the lawsuit.
